Abstract Library

#4574 Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study

Introduction: Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.

Conference:

Presenting Author: Hernando Cubero J

Authors: Rodien-Louw C, Simo-Servat A, Dubois M, Sheppard J, McDonnell M,

Keywords: gastroenteropancreatic neuroendocrine tumour, GEP-NET, acromegaly, lanreotide, LA-SSA, somatostatin, patient preference,

#4239 Implementation of a new, nurse-led clinic (NLC) for neuroendocrine tumor (NET) patients

Introduction: There is international evidence supporting nurse-led services for people with chronic diseases in reducing hospitalisations, symptom improvement and lifestyle, and patient satisfaction. Patients with NET often have high symptoms burden and psychosocial distress in the context of indolent disease. Our centre recently implemented a (NLC) to provide complex care support for patients with NET.

Conference:

Presenting Author:

Authors: Wakelin K, Michael M, Kong G, Rogers M, Natkunarajah N,

Keywords: Nurse-led care, Multidisciplinary care, Supportive care, Symptom management, Patient support,

#4222 Quali-NET: A prospective study on patient-reported quality of life in neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms of the lung (LNEN) or gastro-enteropancreatic tract (GEPNEN) are typically slow-growing, leading to longer overall survival, and resembling chronic illnesses. Therefore, focus on quality of life (QoL) is crucial. While brief studies have been done, comprehensive, long-term studies are needed.

Conference:

Presenting Author: Islam O

Authors: Islam O, Depauw L, van der Massen I, Simoens M, Galdermans D,

Keywords: GEP-NEN, LNEN, Quality of life, Longitudinal data,

#3839 The impact of the COVID-19 pandemic on neuroendocrine tumor (NET) service recovery and patient perceptions in Sheffield NET Centre UK – A quantitative and qualitative analysis 2017-2021

Introduction: The COVID-19 pandemic has affected the delivery of NET services and patient care. To assess the evolution of NET services during and peri-pandemic, we retrospectively analysed NET services and patient perceptions between 2017-2021.

Conference:

Presenting Author: Munir A

Authors: Munir A, Dabke T, Finnen J,

Keywords: COVID-19, NET, Service, Patient Satisfaction, Therapy, Psychology,

#3807 Key device attributes for Somatostatin Receptor Ligand (SRL) therapy in patients with neuroendocrine tumors (NETs)

Introduction: SRL injection effectiveness, safety and adherence are similar for independent vs healthcare setting administration, but patient preferences and satisfaction with devices vary. For other injectable hormones, device ease of use has been associated with more favourable outcomes. Elucidating preferred SRL device features should help HCPs decide which device best fits individual needs.

Conference:

Presenting Author: Martin W

Authors: Martin W, Kolarova T, Marks M, Follin C, de Herder W,

Keywords: NET, neuroendocrine tumor, somatostatin receptor ligands, SRL, device, preference,